These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 22019530)

  • 1. In vitro vs. canine data for assessing early exposure of doxazosin base and its mesylate salt.
    Erceg M; Vertzoni M; Cerić H; Dumić M; Cetina-Čižmek B; Reppas C
    Eur J Pharm Biopharm; 2012 Feb; 80(2):402-9. PubMed ID: 22019530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state.
    Arndt M; Chokshi H; Tang K; Parrott NJ; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2013 Aug; 84(3):633-41. PubMed ID: 23434923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pH-independent sustained release matrix tablet containing doxazosin mesylate: effect of citric acid.
    Cha KH; Tran TH; Kim MS; Kim JS; Park HJ; Park J; Cho W; Hwang SJ
    Arch Pharm Res; 2010 Dec; 33(12):2003-9. PubMed ID: 21191766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
    Shono Y; Jantratid E; Dressman JB
    Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of reduced gastric acid secretion on dissolution of salts of weak bases in the fasted upper gastrointestinal lumen: Data in biorelevant media and in human aspirates.
    Litou C; Vertzoni M; Xu W; Kesisoglou F; Reppas C
    Eur J Pharm Biopharm; 2017 Jun; 115():94-101. PubMed ID: 28214603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers.
    Ma N; Liu W; Li H; Chen B; Zhu Y; Liu X; Wang F; Xiang D; Zhang B
    J Pharm Biomed Anal; 2007 Feb; 43(3):1049-56. PubMed ID: 17055685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
    Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
    Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
    Wei H; Löbenberg R
    Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canine versus in vitro data for predicting input profiles of L-sulpiride after oral administration.
    Fotaki N; Symillides M; Reppas C
    Eur J Pharm Sci; 2005 Nov; 26(3-4):324-33. PubMed ID: 16139490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents.
    Kalantzi L; Persson E; Polentarutti B; Abrahamsson B; Goumas K; Dressman JB; Reppas C
    Pharm Res; 2006 Jun; 23(6):1373-81. PubMed ID: 16715357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of key factors affecting the oral absorption of salts of lipophilic weak acids: a case example.
    Petrakis O; Vertzoni M; Angelou A; Kesisoglou F; Bentz K; Goumas K; Reppas C
    J Pharm Pharmacol; 2015 Jan; 67(1):56-67. PubMed ID: 25252222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma profiles of lycopene after single oral and intravenous administrations in dogs.
    Vertzoni M; Valsami G; Reppas C
    J Pharm Pharmacol; 2006 Sep; 58(9):1211-7. PubMed ID: 16945179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxazosin-carrageenan interactions: a novel approach for studying drug-polymer interactions and relation to controlled drug release.
    Pavli M; Baumgartner S; Kos P; Kogej K
    Int J Pharm; 2011 Dec; 421(1):110-9. PubMed ID: 21963476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of intragastric drug solubility in the fed state: comparison of various media with data in aspirates.
    Diakidou A; Vertzoni M; Dressman J; Reppas C
    Biopharm Drug Dispos; 2009 Sep; 30(6):318-25. PubMed ID: 19644845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix tablets based on carrageenans with dual controlled release of doxazosin mesylate.
    Pavli M; Vrečer F; Baumgartner S
    Int J Pharm; 2010 Nov; 400(1-2):15-23. PubMed ID: 20727957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene.
    Kambayashi A; Dressman JB
    Eur J Pharm Biopharm; 2013 May; 84(1):200-7. PubMed ID: 23262163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of intragastric solubility of drugs: in what medium?
    Vertzoni M; Pastelli E; Psachoulias D; Kalantzi L; Reppas C
    Pharm Res; 2007 May; 24(5):909-17. PubMed ID: 17372688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH.
    Li S; Wong S; Sethia S; Almoazen H; Joshi YM; Serajuddin AT
    Pharm Res; 2005 Apr; 22(4):628-35. PubMed ID: 15846471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3.
    Fuchs A; Leigh M; Kloefer B; Dressman JB
    Eur J Pharm Biopharm; 2015 Aug; 94():229-40. PubMed ID: 26032292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.